Elizabeth Brem News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Chimeric antigen receptor T-cell therapies are already moving into earlier lines of therapy for patients with diffuse large B-cell lymphoma (DLBCL), and now people are looking at when to use bispecific antibodies.

United statesElizabeth bremUniversity of californiaResearch groupSchool of medicineItalian lymphoma foundationAmerican journalItalian lymphomaClinical oncologyCancer agingCart cell therapyBispecific antibodiesDisease management